BrightPath Biotherapeutics Co., Ltd.
4594.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥3,586 | ¥4,235 | ¥10,262 | ¥5,355 |
| - Cash | ¥810 | ¥1,057 | ¥1,531 | ¥2,305 |
| + Debt | ¥25 | ¥113 | ¥0 | ¥88 |
| Enterprise Value | ¥2,801 | ¥3,290 | ¥8,731 | ¥3,138 |
| Revenue | ¥1 | ¥0 | ¥5 | ¥15 |
| % Growth | 1,473.6% | -98.6% | -65.7% | – |
| Gross Profit | ¥1 | -¥0 | ¥3 | ¥12 |
| % Margin | 97.2% | -473.6% | 64.1% | 78.5% |
| EBITDA | -¥1,149 | -¥1,166 | -¥1,467 | -¥1,446 |
| % Margin | -101,434.2% | -1,619,147.2% | -27,783.2% | -9,386.6% |
| Net Income | -¥1,151 | -¥1,168 | -¥1,486 | -¥1,484 |
| % Margin | -101,601.9% | -1,622,336.1% | -28,137% | -9,632.6% |
| EPS Diluted | -14.12 | -18.21 | -24.9 | -28.55 |
| % Growth | 22.5% | 26.9% | 12.8% | – |
| Operating Cash Flow | -¥1,250 | -¥1,157 | -¥1,204 | -¥1,512 |
| Capital Expenditures | -¥1 | -¥8 | -¥2 | -¥18 |
| Free Cash Flow | -¥1,252 | -¥1,165 | -¥1,206 | -¥1,530 |